IL305867A - Method for obtaining tumor-hypoxia educated regenerative macrophages and use thereof in regenerative medicine - Google Patents
Method for obtaining tumor-hypoxia educated regenerative macrophages and use thereof in regenerative medicineInfo
- Publication number
- IL305867A IL305867A IL305867A IL30586723A IL305867A IL 305867 A IL305867 A IL 305867A IL 305867 A IL305867 A IL 305867A IL 30586723 A IL30586723 A IL 30586723A IL 305867 A IL305867 A IL 305867A
- Authority
- IL
- Israel
- Prior art keywords
- mononuclear
- mononuclear phagocytes
- population
- hours
- tumor
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims 14
- 206010028980 Neoplasm Diseases 0.000 title claims 11
- 238000000034 method Methods 0.000 title claims 8
- 230000001172 regenerating effect Effects 0.000 title claims 4
- 206010021143 Hypoxia Diseases 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 6
- 102100027681 Fructose-2,6-bisphosphatase TIGAR Human genes 0.000 claims 5
- 101000651314 Homo sapiens Fructose-2,6-bisphosphatase TIGAR Proteins 0.000 claims 5
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 claims 5
- 102100031347 Metallothionein-2 Human genes 0.000 claims 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 210000001539 phagocyte Anatomy 0.000 claims 4
- 101150054149 ANGPTL4 gene Proteins 0.000 claims 3
- -1 Antxr2 Proteins 0.000 claims 3
- 102100030497 Cytochrome c Human genes 0.000 claims 3
- 102100028183 Cytohesin-interacting protein Human genes 0.000 claims 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 claims 3
- 101150049955 Egln3 gene Proteins 0.000 claims 3
- 102000058062 Glucose Transporter Type 3 Human genes 0.000 claims 3
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims 3
- 101000726355 Homo sapiens Cytochrome c Proteins 0.000 claims 3
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 claims 3
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims 3
- 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 claims 3
- 102100034381 Plexin-A2 Human genes 0.000 claims 3
- 108091006298 SLC2A3 Proteins 0.000 claims 3
- 101150030763 Vegfa gene Proteins 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims 2
- 101150032906 LEP gene Proteins 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 101150035730 Mmp9 gene Proteins 0.000 claims 2
- 101150032346 NDRG1 gene Proteins 0.000 claims 2
- 101150071967 Nupr1 gene Proteins 0.000 claims 2
- 101150117945 PDGFB gene Proteins 0.000 claims 2
- 101100074427 Phormidium laminosum lepB gene Proteins 0.000 claims 2
- 101150016703 Plod2 gene Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001143 conditioned effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101150067167 Adamtsl4 gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150093802 CXCL1 gene Proteins 0.000 claims 1
- 101150064697 CXCL16 gene Proteins 0.000 claims 1
- 101150066398 CXCR4 gene Proteins 0.000 claims 1
- 101150031350 Cxcl2 gene Proteins 0.000 claims 1
- 101150102927 Cxcl3 gene Proteins 0.000 claims 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 101150094945 FCGR3A gene Proteins 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101150013399 ITGA1 gene Proteins 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 101150099102 MMP10 gene Proteins 0.000 claims 1
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 claims 1
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 claims 1
- 239000007757 Media 199 Substances 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 101150101095 Mmp12 gene Proteins 0.000 claims 1
- 101150095652 Mmp14 gene Proteins 0.000 claims 1
- 101150092342 Mmp8 gene Proteins 0.000 claims 1
- 101100066428 Mus musculus Fcgr1 gene Proteins 0.000 claims 1
- 101100334518 Mus musculus Fcgr4 gene Proteins 0.000 claims 1
- 101100017511 Mus musculus Hilpda gene Proteins 0.000 claims 1
- 101100236209 Mus musculus Ltb4r gene Proteins 0.000 claims 1
- 101100038125 Mus musculus Rora gene Proteins 0.000 claims 1
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 claims 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
- 101150055796 Ninj1 gene Proteins 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 101150073988 Rtn4rl2 gene Proteins 0.000 claims 1
- 101150058068 SLC2A1 gene Proteins 0.000 claims 1
- 101150052594 SLC2A3 gene Proteins 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 101150004141 Vcan gene Proteins 0.000 claims 1
- 101150115477 Vldlr gene Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 101150059062 apln gene Proteins 0.000 claims 1
- 101150088826 arg1 gene Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000025645 collagenopathy Diseases 0.000 claims 1
- 101150074488 ddit4 gene Proteins 0.000 claims 1
- 230000004665 defense response Effects 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000006576 neuronal survival Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000020874 response to hypoxia Effects 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000007838 tissue remodeling Effects 0.000 claims 1
- 230000001228 trophic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (18)
1.CLAIMS 1. An in vitro or ex vivo method for inducing a phenotypic and/or functional change in a population of mononuclear phagocytes isolated from biological samples comprising the incubation of said population in a culture medium comprising factors released from tumor cultures or explants, wherein the incubation takes place under hypoxic conditions, and wherein said incubation induces a phenotypic and / or functional change in the mononuclear phagocytes of the population.
2. The method according to claim 1, wherein the mononuclear phagocyte is a monocyte and/or the incubated mononuclear phagocyte population is an in vitro culture of monocytes isolated from biological samples and/or wherein the culture medium comprises factors capable of differentiating monocytes into macrophages, for example the Macrophage colony-stimulating factor (M-CSF).
3. The method according to claim 1 or 2 wherein the population is incubated for from hours or 12 hours to 20 days, more preferably 6 hours-10 days or preferably 6 hours-hours or 3-8 days, even more preferably 18 hours-24 hours or 6 days, even more preferably 18 hours or 7 days.
4. The method according to any one of previous claims, wherein the mononuclear phagocytes induced to the phenotypic and/or functional change are macrophages.
5. The method according to one of the preceding claims, wherein the culture medium comprises a tumor supernatant, said supernatant being preferably obtained from cultures of solid tumor, tumor explants or tumor cell lines, preferably from fibrosarcoma or glioma or preferably being a medium conditioned from the tumor (CTM), preferably produced from tumor cell lines, tumor explants, or solid tumor, or from resections of dissociated and plated in vitro tumors, preferably for a period of about 6 hours-20 days, more preferably of about 12 hours-72 hours.
6. The method according to one of the preceding claims, where the culture medium consists of a cell culture medium, Eagle's minimal essential medium or derivatives thereof, and / or Roswell Park Memorial Institute (RPMI) 1640, and / or Media 199 and / or Fischer's medium and/or or Iscove’s Modified Dulbecco’s Medium (IMDM), and 1-99%, preferably 10-90%, more preferably 30-50%, even more preferably 30% or 50%, medium conditioned from the tumor (CTM) or tumor supernatant.
7. The mononuclear phagocytes, preferably macrophages, obtainable by the method according to any one of claims 1-6, preferably wherein said phagocytes: i) express at least one of the following genes: CXCR4, CYTIP, SLC2A3 and MT2A; and/or ii) express low/no level of at least one of the following genes: PLXNA2, HSPH1, CYCS and TIGAR.
8. An isolated mononuclear phagocyte, preferably macrophage, which: i) expresses at least one of the following genes: CXCR4, CYTIP, SLC2A3 and MT2A; and/or ii) expresses low/no level of at least one of the following genes: PLXNA2, HSPH1, CYCS and TIGAR.
9. A mononuclear phagocyte, preferably a macrophage, of claim 7 or 8 wherein said phagocyte: i) expresses: CXCR4, CYTIP, SLC2A3 and MT2A; and ii) expresses low/no level: PLXNA2, HSPH1, CYCS and TIGAR.
10. The mononuclear phagocyte, preferably a macrophage, of claim 7 or 8 wherein the at least one gene is MT2A.
11. The mononuclear phagocyte, preferably a macrophage, of claim 7 or 8 or 10 wherein the at least one gene is TIGAR.
12. The mononuclear phagocyte, preferably a macrophage, of any one of claims 7-8 or 10-wherein said phagocyte expresses CXCR4, MT2A, is characterized by the expression of MT1x and expresses low/no level of TIGAR.
13. A population of mononuclear phagocytes comprising at least one mononuclear phagocyte of any one of claims 7-12.
14. The mononuclear phagocytes of any one of claims 7-12 or the population of isolated mononuclear phagocytes of claim 13, preferably said mononuclear phagocytes being macrophages, characterized by the expression of at least one of the genes of Table and/or Table 2 and/or Table 3, and/or Table 6 and / or by the secretion of at least one of the molecules of Table 2, preferably by the expression of metalloproteases (for example Mmp8, Mmp9, Mmp10, Mmp12, Mmp14, Mmp19, Mmp27) and / or of trophic factors (for example. VEGFs, FGFs, IGFs) and / or cell contact and adhesion molecules (for example Rap2A, Ninj1, Antxr2, Itga1, Itga6, Itga9, ItgaM, Adamtsl4, Adamtsl6), and / or mediators that promote survival (for example Rtn4rl2) and/or immunomodulation (for example Arg1, Cxcl1, Cxcl2, Cxcl3, Cxcl16, Fcgr1, Fcgr4, Ltb4r1, Jmjd1) and / or from having acquired regenerative properties and /or by the expression of at least one of the genes related to response to wound healing (for example Adm, Bnip3, Pdgfb, Vegfa) and/or angiogenesis (for example Vegfa, Angptl4, Cxcl8, Lep, Rora, Apln) and/or detoxification and regulation of defence response (for example Ndrg1, Mt1e, Mt1f, Mt1g, Mt1h, Mt1x, Mt2a, Mt3, Ddit4, Nupr1) and/or response to hypoxia (for example Hk2, Pfkfb3, Slc2a1, Slc2a3, Cxcr4, Plin2, Adm, Bnip3, Lep, Rora, Ndrg1, Egln3, Mt3, Plod2, Hilpda, Angptl4) and/or extracellular matrix remodelling (for example Mmp9, Vcan, Fgf11, Cxcl8, Lep, Pdgfb, Plod2, Vegfa, Angptl4, Sulf2, Egln3) and/or and neuronal survival and myelination (for example Mt3, Jam2, Vldlr, Nupr1, Egln3).
15. The mononuclear phagocytes of any one of claims 7-12 or 14 or the population of isolated mononuclear phagocytes of claim 13 or 14, preferably said mononuclear phagocytes being macrophages, for medical use.
16. The mononuclear phagocytes of any one of claims 7-12 or 14 or the population of isolated mononuclear phagocytes of claim 13 or 14, preferably said mononuclear phagocytes being macrophages, for use in cell therapy and/or regenerative medicine, preferably in tissue or cell repair, in tissue or cell regeneration, in tissue remodeling, in the treatment and / or in the repair and / or in the healing of wounds, tissue loss in wounds, surgical ulcers, diabetic wounds, in the treatment of conditions of degeneration, including neurodegeneration, retinal degeneration, degeneration due to genetic diseases (such as ALS), autoimmune diseases (arthritis, collagenopathies) or even diabetes in which degeneration of pancreatic islets occurs, in the treatment and / or resolution of inflammation, of inflammation of the tissues, in the treatment of damages, damaged tissues and the like, preferably in the treatment of lesions characterized by loss of central nervous system embedded tissue, preferably in the treatment of a spinal lesion or injury, such as a severe spinal injury, or spinal cord injury, preferably a severe or contusive spinal cord injury.
17. The mononuclear phagocytes or the population of isolated mononuclear phagocytes for use according to claim 15 or 16, preferably said mononuclear phagocytes being macrophages, for use according to claim 14 or 15, where the phagocytes are administered from 2 days to 60 days or to 1 year after the lesion, preferably 4-21 or 15-days after the lesion.
18. Pharmaceutical composition comprising the mononuclear phagocytes of any one of claims 7-12 or 14 or the population of isolated mononuclear phagocytes of claim 13 or 14, preferably said mononuclear phagocytes being macrophages, and at least one pharmaceutically acceptable excipient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000006569A IT202100006569A1 (en) | 2021-03-18 | 2021-03-18 | METHOD FOR OBTAINING REGENERATIVE MACROPHAGES EDUCATED FROM TUMOR AND THEIR USE IN REGENERATIVE MEDICINE |
| PCT/EP2022/057246 WO2022195114A1 (en) | 2021-03-18 | 2022-03-18 | Method for obtaining tumor-hypoxia educated regenerative macrophages and use thereof in regenerative medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305867A true IL305867A (en) | 2023-11-01 |
Family
ID=76523293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305867A IL305867A (en) | 2021-03-18 | 2022-03-18 | Method for obtaining tumor-hypoxia educated regenerative macrophages and use thereof in regenerative medicine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240150716A1 (en) |
| EP (1) | EP4308693A1 (en) |
| JP (1) | JP2024512001A (en) |
| KR (1) | KR20230157465A (en) |
| CN (1) | CN117425724A (en) |
| AU (1) | AU2022239859A1 (en) |
| BR (1) | BR112023018790A2 (en) |
| CA (1) | CA3207905A1 (en) |
| IL (1) | IL305867A (en) |
| IT (1) | IT202100006569A1 (en) |
| WO (1) | WO2022195114A1 (en) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4744933A (en) | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
| US4749620A (en) | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
| JPH0628570B2 (en) | 1986-02-13 | 1994-04-20 | 雪印乳業株式会社 | Method and device for manufacturing capsule body |
| EP0301777A1 (en) | 1987-07-28 | 1989-02-01 | Queen's University At Kingston | Multiple membrane microencapsulation |
| US5089272A (en) | 1989-03-29 | 1992-02-18 | Snow Brand Milk Products Co., Ltd. | Process for producing capsules having a permeability-controllable membrane |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5578442A (en) | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| EP0802800B1 (en) | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| EP3508207B1 (en) * | 2016-08-30 | 2021-08-11 | Niigata University | Cell preparations cultivated under low oxygen and sugar conditions, and their uses in therapy. |
| DK3299453T3 (en) * | 2016-09-23 | 2019-08-12 | Xcell Medical Solutions S L | CELL THERAPY WITH POLARIZED MACROPHAGES FOR Tissue regeneration |
| WO2020169472A2 (en) * | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
-
2021
- 2021-03-18 IT IT102021000006569A patent/IT202100006569A1/en unknown
-
2022
- 2022-03-18 EP EP22716392.0A patent/EP4308693A1/en active Pending
- 2022-03-18 CN CN202280022465.XA patent/CN117425724A/en active Pending
- 2022-03-18 US US18/550,232 patent/US20240150716A1/en active Pending
- 2022-03-18 BR BR112023018790A patent/BR112023018790A2/en unknown
- 2022-03-18 IL IL305867A patent/IL305867A/en unknown
- 2022-03-18 JP JP2023557317A patent/JP2024512001A/en active Pending
- 2022-03-18 KR KR1020237035351A patent/KR20230157465A/en unknown
- 2022-03-18 AU AU2022239859A patent/AU2022239859A1/en active Pending
- 2022-03-18 CA CA3207905A patent/CA3207905A1/en active Pending
- 2022-03-18 WO PCT/EP2022/057246 patent/WO2022195114A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| IT202100006569A1 (en) | 2022-09-18 |
| EP4308693A1 (en) | 2024-01-24 |
| BR112023018790A2 (en) | 2023-12-12 |
| AU2022239859A1 (en) | 2023-10-12 |
| KR20230157465A (en) | 2023-11-16 |
| CA3207905A1 (en) | 2022-09-22 |
| JP2024512001A (en) | 2024-03-18 |
| WO2022195114A1 (en) | 2022-09-22 |
| CN117425724A (en) | 2024-01-19 |
| US20240150716A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cai et al. | Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential | |
| Xuan et al. | Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance | |
| Ejaz et al. | Understanding the mechanism of radiation induced fibrosis and therapy options | |
| Gjorgieva et al. | Mesenchymal stem cells for anti-cancer drug delivery | |
| Kanninen et al. | Applications of the Keap1–Nrf2 system for gene and cell therapy | |
| Hulou et al. | Experimental therapies: gene therapies and oncolytic viruses | |
| EP3437650A1 (en) | Treatment of local skin hypotrophy conditions | |
| Zhuang et al. | Exosome secreted by human gingival fibroblasts in radiation therapy inhibits osteogenic differentiation of bone mesenchymal stem cells by transferring miR-23a | |
| Sun et al. | Emerging role of IL-10 in hypertrophic scars | |
| Yang et al. | Exosomal microRNAs have great potential in the neurorestorative therapy for traumatic brain injury | |
| Kalkan | Hypoxia is the driving force behind GBM and could be a new tool in GBM treatment | |
| Zhang et al. | Role of Butylphthalide in Immunity and Inflammation: Butylphthalide May Be a Potential Therapy for Anti‐Inflammation and Immunoregulation | |
| IL305867A (en) | Method for obtaining tumor-hypoxia educated regenerative macrophages and use thereof in regenerative medicine | |
| CN107982536B (en) | Composition of drug action target and application | |
| RU2023126518A (en) | METHOD FOR OBTAINING TUMOR-HYPOXIA-TRAINED REGENERATIVE MACROPHAGES AND THEIR APPLICATION IN REGENERATIVE MEDICINE | |
| CN113227384B (en) | Pharmaceutical compositions, kits and methods for treating tumors | |
| Shi et al. | Effect of inflammatory reaction mediated by microglia polarization in spinal cord injury | |
| Gomer | Circulating progenitor cells and scleroderma | |
| Wang et al. | The effects of mesenchymal stem cells on the chemotherapy of colorectal cancer | |
| RU2676701C1 (en) | Agent for repression of death of neurons in ischemic stroke of brain and method of cell-mediated gene therapy for ischemic stroke of brain by repression of death of neurons in ischemic stroke of brain | |
| JP2015521476A (en) | Improving the immunomodulatory effect of cells | |
| Radaei et al. | Promising Effects of Zerumbone on the Regulation of Tumor-promoting Cytokines Induced by TNF-α-activated Fibroblasts | |
| Cirves et al. | Neutrophil Granulopoiesis Optimized Through Ex Vivo Expansion of Hematopoietic Progenitors in Engineered 3D Gelatin Methacrylate Hydrogels | |
| KR101673318B1 (en) | Cell therapy composition for healing wounds comprising mesenchymal stem cell or the culture medium treated with silver nano particle | |
| Xiong et al. | Synergistic effect of Mn-Si-COS on wound immune microenvironment by inhibiting excessive skin fibrosis mediated with ROS/TGF-β1/Smad7 signal |